Trinseo (NYSE: TSE), a global materials solutions provider and manufacturer of plastics, latex binders and synthetic rubber, will introduce its portfolio of thermoplastic elastomers (TPEs) for medical devices at two major industry shows: MD&M West in Anaheim, Calif. from February 5-7 at Booth 1986 and Pharmapack EU in Paris from February 6-7 at Booth D94. This portfolio of TPEs complements Trinseo’s traditional rigid plastics offering, making Trinseo a one-stop-shop for both hard and soft plastics.
Trinseo has supported the medical devices market for nearly three decades and is known for superior product quality, outstanding consistency, and a focus on customer compliancy requirements. The expanded portfolio enhances Trinseo’s offering with soft touch materials and overlays that are often needed with hard plastics.
TPEs can serve as a vinyl substitute. With their elastomeric composition, TPEs can allow better handling of medical devices and potentially increase performance, functionality, usability, and aesthetics, while helping to improve patient care and contribute to patient safety.
“We've brought together a very high quality portfolio of rigid plastics with TPEs that have been specifically formulated for the medical devices sector,” said Aldo Zanetti, business unit manager TPE Solutions - Medical & Packaging for Trinseo. “This move helps us meet the needs of medical customers, particularly as the industry addresses trends in health care that require medical devices and equipment that are more patient friendly and service provider friendly.”
Trinseo offers two styrenic block copolymers (TPSs) to the medical devices industry under the brands MEGOL™ and RAPLAN™. Materials are biocompatibility tested and available with full biocompatibility (MED) and limited testing approved for skin contact (SK), providing customers with the most economical material option, since not all medical devices require full biocompatibility.
Trinseo’s rigid plastics for medical devices include:
Trinseo supports medical devices customers with material solutions for Single and Multiple Use Devices, Equipment Housings, Drug Delivery Systems, and Medical Wearables. As the medical industry continues to evolve and bring life-enhancing devices to market, global medical device and pharmaceutical manufacturers rely on Trinseo to respond with materials developed to meet their needs. The company adheres to current Good Manufacturing Practices (cGMP) and holds an ISO 13485 certification.
Trinseo (NYSE:TSE) is a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber with a focus on delivering innovative, sustainable, and value-creating products that are intrinsic to our daily lives. Trinseo is dedicated to making a positive impact on society by partnering with like-minded stakeholders, and supporting the sustainability goals of our customers in a wide range of end-markets including automotive, consumer electronics, appliances, medical devices, packaging, footwear, carpet, paper and board, building and construction, and tires. Trinseo had approximately $3.0 billion in net sales in 2020, with 17 manufacturing sites around the world, and approximately 2,600 employees. For more information, please visit: www.trinseo.com.
Cautionary Note on Forward-Looking Statements
This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like "expect," "anticipate," "intend," "forecast," "outlook," "will," "may," "might," "see," "tend," "assume," "potential," "likely," "target," "plan," "contemplate," "seek," "attempt," "should," "could," "would" or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on our current expectations and assumptions regarding the timing of the proposed acquisition of the Arkema MMA and PMMA business (the "Acquisition"); estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities and cost synergies relating to the Acquisition, our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause such a difference include, but are not limited to, our failure to complete the Acquisition or meet the conditions to closing, including antitrust, works council and other regulatory approvals; the failure to obtain the financing necessary to fund the Acquisition and the impact of the substantial indebtedness to be incurred; costs related to the Acquisition; following the Acquisition, our ability to successfully integrate the acquired businesses, generate expected cost savings and synergies, maintain relationships with customers, retain key employees and profitably grow the business; and those factors discussed in our Annual Report on Form 10-K, under Part I, Item 1A —"Risk Factors" and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.